KINGSLEY OYEM: Open Payments
NPI 1477062347 · JERSEY CITY, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,076 in 56 payments from 9 companies in 2025. Trend: 2023 $1,394 · 2024 $1,317 · 2025 $1,076
Food & beverage: $1,076
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 31 | $422 |
| E.R. Squibb & Sons, L.L.C. | 8 | $341 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $84 |
| Vanda Pharmaceuticals Inc. | 4 | $71 |
| Otsuka America Pharmaceutical, Inc. | 4 | $64 |
| Lundbeck LLC | 2 | $38 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Neurocrine BioSciences, Inc. | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
Products named: VRAYLAR, COBENFY, REXULTI, CAPLYTA, FANAPT, UZEDY, INGREZZA, Qelbree.
Industry payments across NJ — which companies pay providers there.
